" class="no-js "lang="en-US"> Oncoustics - Medtech Alert
Sunday, May 26, 2024
Oncoustics | Pharmtech Focus


About Oncoustics


Oncoustics applies AI to raw ultrasound signals to do tissue characterization at point of care for low-cost, noninvasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. The Oncoustics solutions for ultrasound will be submitted for regulatory approval in the United States (FDA 510(k)), Canada (Health Canada medical device license) and the European Union (CE Mark). The OnX Liver Assessment Solution has not been cleared for clinical use and is For Investigational Use Only.

Related Story

Oncoustics Closes New Funding to Advance its AI Innovations in Ultrasound and Address Huge Unmet Clinical Needs in Liver Disease

July 22 2022

Oncoustics (http://www.oncoustics.com), the leader in ultrasound-based tissue characterization solutions announces the initial close of a […]